Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.

Neuroradiology · 2010 · PMC2938443 · PMID 20049424

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Also, we found a moderate but highly significant PBVC of −0.33% in a group of untreated RRMS patients within a period of 6 months.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.